Glibenclamide therapy in diabetes mellitus.
In an initial trial of glibenclamide in the treatment of maturity onset diabetes mellitus 28 patients were treated for up to one year and no toxic effects or side-effects were encountered. The hypoglycaemic potency of this drug is such that 5 mg. of glibenclamide corresponds to about 1,500 mg. of tolbutamide and 375 mg. of chlorpropamide.
D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000032:analysis; D002747:Chlorpropamide / Q000008:administration & dosage; D003920:Diabetes Mellitus / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D014044:Tolbutamide / Q000008:administration & dosage
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D014044:Tolbutamide; D002747:Chlorpropamide